Oxford Immunotec Global PLC Profit Margin

The latest profit margin for OXFD is -30.51% as of September 2020. That compares with 198.51% in the prior-year period — down 115.4% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Oxford Immunotec Global PLC's historical trend and sector peers before judging valuation or financial health.

Over the past year, OXFD's profit margin moved from 198.51% to -30.51% — a 115.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oxford Immunotec Global PLC's valuation or profitability profile.

Against Healthcare companies, OXFD currently prints -30.51% for profit margin, while the sector average sits near 13.89%. That is roughly 319.6% below the sector mean. Large gaps often invite a closer look at Oxford Immunotec Global PLC's growth, margins, and balance sheet.

Profit Margin shows how effectively Oxford Immunotec Global PLC converts resources into returns. At -30.51%, OXFD may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 198.51% in the prior-year period — down 115.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting OXFD's profit margin (-30.51%), review year-over-year change from 198.51%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.